Key result
Tissue-specific promoters and novel enhancers show potential to refine transcriptional targeting in cardiac gene therapy.
Why the study?
Cardiac-targeted transgene delivery offers new treatments for cardiovascular diseases, and restricting gene transfer to cardiac tissue via transcriptional cis-regulatory elements may protect extracardiac organs from side effects.
Transcriptional targeting using specific promoters and enhancers offers a promising strategy to restrict AAV-mediated gene expression to the heart, minimizing off-target effects.
Supports preclinical AAV vector optimization; leaves open clinical translation and safety data.
Cardiac-targeted transgene delivery offers new treatment opportunities for cardiovascular diseases, which massively contribute to global mortality. Restricted gene transfer to cardiac tissue might protect extracardiac organs from potential side-effects. This could be mediated by using cis-regulatory elements, including promoters and enhancers that act on the transcriptional level. Here, we discuss examples of tissue-specific promoters for targeted transcription in myocytes, cardiomyocytes, and chamber-specific cardiomyocytes. Some promotors are induced at pathological states, suggesting a potential use as "induction-by-disease switches" in gene therapy. Recent developments have resulted in the identification of novel enhancer-elements that could further pave the way for future refinement of transcriptional targeting, for example, into the cardiac conduction system.
No takes yet. Share an insight, caveat, or question.
Schröder et al. (2023) conducted a review in Cardiovascular diseases. Cardiac-targeted transgene delivery using AAV vectors was evaluated. Cardiac-targeted transgene delivery using tissue-specific promoters and novel enhancer-elements offers potential for refining transcriptional targeting in gene therapy for cardiovascular diseases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: